Cargando…

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer

BACKGROUND: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. FINDINGS: In an exploratory study, we determined the CYP2D6 metabolic status a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Love, Richard R, Desta, Zuerenesay, Flockhart, David, Skaar, Todd, Ogburn, Evan T, Ramamoorthy, Anuradha, Uy, Gemma B, Laudico, Adriano V, Van Dinh, Nguyen, Quang, Le Hong, Van To, Ta, Young, Gregory S, Hade, Erinn, Jarjoura, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584248/ https://www.ncbi.nlm.nih.gov/pubmed/23476897 http://dx.doi.org/10.1186/2193-1801-2-52

Ejemplares similares

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
por: Binkhorst, Lisette, et al.
Publicado: (2015)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Follow up after sample size re-estimation in a breast cancer trial for time to recurrence
por: Hade, Erinn, et al.
Publicado: (2013)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles
por: Agudelo, Daniel, et al.
Publicado: (2013)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Inter-country and ethnic variation in colorectal cancer survival: Comparisons between a Philippine population, Filipino-Americans and Caucasians
por: Redaniel, Maria Theresa, et al.
Publicado: (2010)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Generation of brain tumours in mice by Cre-mediated recombination of neural progenitors in situ with the tamoxifen metabolite endoxifen
por: Benedykcinska, Anna, et al.
Publicado: (2016)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021)

Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients
por: Maggadani, Baitha Palanggatan, et al.
Publicado: (2021)

Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels
por: Dickschen, Kristin J. R., et al.
Publicado: (2017)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US
por: Redaniel, Maria Theresa M, et al.
Publicado: (2009)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
por: Jager, N. G. L., et al.
Publicado: (2012)

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen
por: Ahmad, A, et al.
Publicado: (2016)

The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
por: Helland, Thomas, et al.
Publicado: (2015)

Applicability of the hour of life approach in hyperbilirubinemia among Filipino term infants
por: Villanueva-Uy, Maria Esterlita T., et al.
Publicado: (2022)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer
por: Hennig, Ewa E., et al.
Publicado: (2015)

Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
por: Weissenstein, U., et al.
Publicado: (2019)

Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer
por: Lo, Tom Edward Ngo, et al.
Publicado: (2015)

Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice
por: Chen, Paul, et al.
Publicado: (2018)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Topical Endoxifen for Mammographic Density Reduction—A Randomized Controlled Trial
por: Bäcklund, Magnus, et al.
Publicado: (2022)

Dentinogenesis Imperfecta and Caries in Osteogenesis Imperfecta among Vietnamese Children
por: Nguyen, Huong Thi Thu, et al.
Publicado: (2021)

Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report
por: Henderson, Sara L., et al.
Publicado: (2016)

Differences in Tobacco Use Among a Sample of At-Risk Chinese, Filipino, and Vietnamese Adult Men Living in the SF Bay Area
por: Toleran, Daniel E, et al.
Publicado: (2019)

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
por: Henry, N L, et al.
Publicado: (2010)

The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014)

Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
por: Thanvi, Vikas
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7dp28ctm2j341js5v5e6gmqdr2